A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...